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GPR81 (G-protein-coupled receptor 81), GPR109a, and GPR109b form the hydroxycarboxylic acid receptor 
subfamily.1 Encoded by the HCAR1 gene, GPR81 is predomi-
nantly expressed in brown and white adipose tissue.2 L-lactate 
is the endogenous ligand with an EC
50
 of ≈5 mmol/L.3 Lactate, 
formed from pyruvate during anaerobic glycolysis, has a 
physiological plasma concentration of 0.5 to 2 mmol/L, rising 
from 10 to 30 mmol/L during intense exercise or prolonged 
hypoxia.4,5 This suggests that GPR81 is either physiologically 
quiescent basally or that it is primarily responsive to the local, 
rather than circulating, concentration of lactate. In adipocytes, 
activation of GPR81 by L-lactate prevents lipid breakdown 
and promotes storage of energy-rich metabolites in adipo-
cytes.2,6 Synthetic GPR81 agonists7–9 are potential therapies 
for dyslipidemia and inhibit lipolysis in cultured adipocytes 
and in vivo.
GPR81 is also expressed in brain, kidney, liver, skeletal 
muscle,2,6 and immune cells,10 but the function in nonadipose 
tissue is poorly defined and the limited data is somewhat con-
tradictory. In mouse macrophages and human monocytes, 
GPR81 activation suppresses Toll-like receptor pathways, 
preventing NLRP3 (NACHT, LRR and PYD domains-con-
taining protein 3) inflammasome activation and cell death.11 
This mechanism appears protective, with receptor activation 
reducing tissue injury in models of hepatitis, pancreatitis,11 
and colitis.12 GPR81 inhibition/knockdown has also been 
shown to be protective, enhancing neuron survival in cere-
bral ischemia13 and slowing cancer growth,14,15 partly due to 
effects on the vasculature. For example, GPR81 knockdown 
in a breast cancer cell line suppressed VEGF (vascular en-
dothelial growth factor) and amphiregulin, retarding angi-
ogenesis.14 Similarly, in the sensorimotor cortex of GPR81 
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potent vasoconstrictor ET-1. This suggests that lactate may be a paracrine regulator of renal blood flow, particularly 
relevant when extracellular lactate is high as occurs during ischemic renal disease.  (Hypertension. 2020;75:00-00. DOI: 
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knockout mice (Gpr81−/−), the induction of VEGF-A and 
increased capillary density by either treadmill exercise or 
subcutaneous lactate injections was absent.16 Ex vivo lactate 
infusion in the rat retina decreases capillary lumen diameter,17 
suggesting vasomotor effects of GPR81 activation. Indeed, a 
small molecule GPR81 agonist, AZ2 (aka AZ′5538), which 
suppressed in vivo free fatty acid levels, also increased blood 
pressure (BP) when infused intravenously.9 Nonselective 
α-adrenoceptor antagonism and endothelin receptor blockade 
separately reduced this pressor effect.9
The concept that lactate could influence blood pres-
sure (BP) through activation of GPR81 is relevant to human 
health. In the current study, we used AZ′5538 and Gpr81−/− 
mice to resolve the effects of GPR81 activation on BP and 
renal hemodynamics in mice and further demonstrated that 
genetic deletion of the receptor conferred protection against 
renal ischemia-reperfusion injury.
Methods
See in the Data Supplement for detailed methods. The data that 
support the findings of this study are archived in the University of 
Edinburgh data storage and available from the corresponding author 
upon reasonable request.
Experiments were performed on adult male C57Bl/6JCrl (Charles 
River, Paris, France) or adult male Gpr81+/+ (wild-type) and Gpr81−/− 
(knockout) mice on a C57BL/6JOlaHsd background.9 Experiments 
were performed under a UK Home Office Licence following ethical 
review by the University of Edinburgh.
In Vivo Measurement of BP and Renal Function
In anesthetized mice, either AZ′5538 (1 µmol/kg bw/min) or 5% 
d-mannitol vehicle was infused intravenously for 15 minutes. BP was 
measured via a carotid cannula and renal hemodynamics measured via 
a Doppler transit time probe, and Doppler flux probes were inserted 
into the cortex and medulla. Separately, renal artery blood flow (RBF) 
was measured noninvasively by Pulse-wave Doppler (Vevo770 and 
707B 30 MHz ultrasound probe; VisualSonics, Canada). Glomerular 
filtration rate (GFR) was measured by Fluorescein isothiocyanate-
inulin clearance before and after administration of AZ′5538.
In Vivo Blockade of Endothelin Receptors
Anesthetized C57Bl/6JCrl mice had separate intravenous infusion 
of AZ′5538 and endothelin receptor antagonists or their corre-
sponding vehicles. Bosentan, a mixed endothelin receptor antago-
nist, was used at 20 and 40 mg/kg; BQ123 (endothelin-A receptor 
antagonist) and BQ788 (endothelin-B receptor antagonist) were 
used at 1 and 2 mg/kg.
Ischemia-Reperfusion Injury (IRI)
Male Gpr81−/− and wild-type littermates were subject to 27 minutes 
of renal pedicle clamping (reperfusion was confirmed visually) fol-
lowed by nephrectomy of the nonclamped kidney. After 6 days, mice 
were killed by cervical dislocation and the kidney taken for mRNA 
extraction and analysis.
RNA Analysis
Polymerase chain reaction (PCR) was used to determine if Gpr81 
was expressed in arteries. Subsequently, RNAscope in situ hybridi-
zation was used to localize Gpr81 in artery and kidney sections. For 
quantitative PCR, RNA was extracted from quarter kidneys (RNeasy 
Mini Kit, Qiagen) and used to assess mRNA abundance by real-time 
quantitative PCR (Universal Probe Library; Sigma Aldrich). To assess 
Gpr81 expression in defined populations of renal cells, kidneys from 
male mice were dissociated into a single-cell suspension and incu-
bated with the following rat anti-mouse antibodies: PDGFRβ (Platelet 
Derived Growth Factor Receptor Beta), CD31 (cluster of differentia-
tion 31), LTL (Lotus tetragonolobus lectin), and F4/80. Fluorescence-
activated cell sorting was performed using the fluorescence-activated 
cell sorting Aria II (BD Biosciences) using 4′,6-diamidino-2-phenyl-
indole to determine live cells. Cells were sorted into lysis buffer and 
RNA extracted using RNeasy microkit (Qiagen), quality checked by 
Agilent Bioanalyser (RNA integrity number >8), and amplified cDNA 
made from the RNA using Ovation RNA-Seq System V2 (NuGen).
Endothelin-1
ET-1 (endothelin-1) was measured by ELISA (R&D Systems, United 
Kingdom). ET-1 protein concentrations were normalized to total protein 
(Pierce BCA assay; Thermo Fisher, United Kingdom).
Statistics
All data are mean±SD. After confirming normal distribution, statis-
tical comparisons (Graphpad Prism 6, La Jolla, CA) were made by 
using 1-sample t test (comparing against a value of 0), unpaired t test, 
and 1- or 2-way ANOVA. For 2-way ANOVA, the main effects of the 
genotype/treatment and time were assessed, and the interaction be-
tween them. Planned comparisons were made using Holm-Sidak with 
a family P value fixed at 0.05.
Results
Activation of GPR81 Increases BP and Decreases 
RBF
In anesthetized male C57BL/6J mice, baseline systolic BP 
(SBP) was 86±9 mm Hg, diastolic BP (DBP) was 69±11 
mm Hg, and heart rate was 284±38 bpm. AZ′5538 increased 
SBP (Figure 1A; ANOVA effect of treatment P=0.0013; effect 
of time and interaction P<0.0001) and DBP (Figure 1B; 
ANOVA effect of treatment P=0.0094; effect of time and inter-
action P<0.0001). The peak BP increases were 13±4 mm Hg 
and 11±3 mm Hg for SBP and DBP, respectively (Figure 1C). 
Heart rate fell with infusion of AZ′5538 compared with 5% 
mannitol vehicle (Figure 1D). All mice received a second in-
fusion of AZ′5538, 35 minutes after the first administration. 
The pressor response to the second administration was attenu-
ated, particularly in DBP (Figure S1 in the Data Supplement).
RBF was measured in 2 different groups of mice by di-
rect Doppler ultrasound with a probe around the right renal 
artery (baseline RBF =0.60±0.23 mL/min) and by pulse-
wave Doppler (baseline velocity =275±21 mm/s). AZ′5538 
infusion significantly decreased RBF, by ≈50% measured by 
flow probe (Figure 1E; ANOVA effect of treatment P=0.027; 
effect of time and interaction P<0.0001) and by ≈30% by 
pulse-wave Doppler (Figure S2; peak decrease of −186±26 
mm/s; ANOVA drug treatment P=0.0002, time and interaction 
P<0.0001). In another experiment, GFR was measured, and 
the mice were then randomized to receive continued intrave-
nous vehicle (n=8) or AZ′5538 (n=8). There was no signifi-
cant change in GFR with vehicle but AZ′5538 infusion caused 
GFR to fall significantly (Figure 1F).
The Cardiovascular Effects of AZ′5538 Are 
Mediated Via Gpr81
BP and heart rate were comparable in Gpr81−/− mice and 
wild-type littermates (Table S3). In wild types, AZ′5538 
significantly increased SBP (Figure 2A; P<0.0001 for main 
effects of genotype and time and for interaction) and DBP 
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time and for interaction) and decreased heart rate (Figure 
S3; ANOVA genotype P=0.025, time P=0.003, and interac-
tion P<0.0001), consistent with our data in C57BL/6J mice. 
AZ′5538 did not increase BP in Gpr81−/− mice.
RBF decreased significantly with AZ′5538 infusion in 
wild-type mice but remained unchanged in Gpr81−/− mice 
(Figure 2C; ANOVA genotype P=0.008 interaction and time 
P<0.0001). Renal vascular resistance did not differ between 
genotypes, although the interaction was significantly different 
(Figure 2D; ANOVA genotype P=0.151, time P=0.022, and 
interaction P=0.0002). AZ′5538 reduced renal cortical per-
fusion but only in wild-type mice (Figure 2E; genotype 
P=0.0003 and time interaction P<0.0001). Medullary flux 
also fell in wild-type mice but not in the Gpr81−/− (Figure 2F; 
genotype P=0.070, time and interaction P<0.0001). Baseline 
GFR was not different between genotype. AZ′5538 reduced 






Figure 1. Effect of AZ′5538 infusion on blood pressure (BP) and renal hemodynamics. Mice were infused intravenously with vehicle (5% mannitol; n=6, 
open squares) or AZ′5538 (1 µmol/[kg·min]; n=6 black circles) for 15 minutes. Systolic blood pressure (A; SBP), diastolic blood pressure (B; DBP), peak 
BP responses (C), and heart rate (D). E, Renal artery blood flow (RBF) in separate mice infused with vehicle (n=6) or AZ′5538 (n=6). F, Glomerular filtration 
rate (GFR) before and after infusion with AZ′5538 (n=8), compared to vehicle (n=8). Data are mean±SD, and for C and F, individual datapoints are shown. 
Statistical comparisons were made by 2-way ANOVA for the main effects of treatment, of time and of the interaction (see text for P values) and by unpaired t 
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P=0.001 by 1-sample t test; n=6) but not in Gpr81−/− mice 
(Figure 4; ΔGFR=−39±83 µL/min; P=0.303; n=6).
Expression of Gpr81 in Arteries and Kidney
Gpr81 was expressed in aorta, renal, and mesenteric arter-
ies (Figure 3A). Separately, quantitative PCR was used to 
assess Gpr81 expression in fluorescence-activated cell sort-
ing–isolated renal cell populations (Figure 3B; n=4 mice). 
Gpr81 mRNA was highly expressed in PDGFRβ+ cells (peri-
cytes) from all 4 samples, identified in only one of 4 samples 
of CD31+ cells (endothelial) and was undetectable in LTL 
(renal tubules) and F4/80 (macrophage) cell populations. 
Using in situ hybridization on whole kidney sections, Gpr81 
was localized in the cortex and medulla of wild-type but not 
Gpr81−/− mice (Figures 4A through 4D). The staining in the 
cortex was localized mainly to the glomeruli (Figure 4A 
and Figure S4), particularly at the vascular pole, consistent 
with localization in arterioles. Gpr81 was also expressed 
in the medulla (Figure 4C) and did not co-localize with the 
nuclear stain. We examined Gpr81 expression in aorta and 
renal artery (Figure 4E and 4F), observing positive stain-
ing in the medial layer, indicating localization to vascular 
smooth muscle cells. No staining was visible in arteries from 
Gpr81−/− mice (Figure S5).
Cardiorenal Effects of GPR81 Activation Are 
Endothelin-1 Dependent
AZ′5538 infusion significantly increased plasma ET-1 con-
centration (Figure 5A) without changing the amount in aorta 
or whole kidney homogenates (Figure S6); renal expression 
of Edn1 was lower in mice that had received a 15-minute in-
fusion of AZ′5538 (Figure S6). To assess functional crosstalk 
between GPR81 and the endothelin system, wild-type mice 
were pretreated with bosentan, before infusion of AZ′5538. 
Bosentan pretreatment at 40 mg/kg did not change the peak 
pressor response to AZ′5538 but significantly blunted the 
sustained effect on BP (Figure 5B; treatment P=0.024, time 
P<0.0001, and interaction P=0.064); similar actions were also 
observed at the 20 mg/kg bosentan. Next, we used pretreat-




Figure 2. Blood pressure and hemodynamic effects of AZ′5538 are GPR81 (G-protein-coupled receptor 81) dependent. Gpr81−/− mice (open circles; n=6) 
and wild-type littermates (closed squares; n=6) were infused intravenously with vehicle (5% mannitol) or AZ′5538 (1 µmol/[kg·min]; n=6 black circles) for 15 
minutes. Systolic blood pressure (SBP, A), diastolic blood pressure (DBP, B), renal artery blood flow (RBF, C), renal vascular resistance (D), perfusion of the 
renal cortex (E), and perfusion of the renal medulla (F) ΔTPU= change in Total Perfusion Units. All data are mean±SD from baseline. Statistical comparisons 
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not changed by either BQ123 or BQ788 (Figure S7). BQ123 
at 2 mg/kg largely prevented the pressor effect of GPR81 
activation, and there was no sustained BP rise in this group 
(Figure 5C and Figure S8; BQ123 treatment P=0.044, time 
P<0.0001, and interaction P=0.988). BQ788 did not change 
the BP response to AZ′5538 (Figure 5D and Figure S8).
Gpr81−/− Mice Are Protected From Renal Ischemia-
Reperfusion Injury
In wild-type mice, renal ischemia significantly increased 
the mRNA expression of the tubule injury marker KIM-1 
(Kidney Injury Molecule 1) (Figure 6A), the fibrosis marker 
collagen 1a1 (Figure 6B), the inflammatory cytokines TNF-α 
(Tumor necrosis factor alpha; Figure 6C), MCP-1 (monocyte 
chemotactic protein 1; Figure 6D), CXCL-1 (C-X-C Motif 
Chemokine Ligand-1; Figure 6E), CXCL-10 (C-X-C Motif 
Chemokine Ligand-10; Figure S9A), and the pan-macrophage 
marker F4/80 (Figure S9B). ET-1, assessed by renal expres-
sion of Edn1 mRNA, was also increased by injury (Figure 6F). 
The transcriptional response to IRI was significantly blunted 
in Gpr81−/− mice. Injury did not affect endothelin-A receptor 
expression in either genotype (Figure S9C); endothelin-B 
receptor expression was reduced in both genotypes by IRI 
(Figure S9D).
Discussion
A decade ago, the orphan receptor GPR81 was shown 
to be activated with low affinity by L-lactate and α- and 
γ-hydroxybutyrate.6 GPR81 mRNA was enriched in mouse 
and human adipocytes and receptor activation by lactate 
inhibited lipolysis.6 GPR81 mRNA expression was also found 
in nonadipose tissue, with expression in the highly vascular-
ized tissues of heart, skeletal muscle, and kidney being ≈10% 
of that in adipocytes.6 Here, we detected GPR81 mRNA in 
whole kidney homogenates. In each of 3 artery types exam-
ined, GPR81 localized to the smooth muscle layer. Transgenic 
fluorescent-reporter mice show GPR81 expression in the 
vessel wall of pial arteries.16 Single-cell RNA sequencing 
detected GPR81 in cerebral and lung vascular smooth muscle 
cells.18 GPR81 has been identified in cultured human umbil-
ical vein endothelial cells,19 but we suggest this is not a major 
expression site, finding discernable levels in only 1 of 4 iso-
lated renal endothelial cell samples and no in situ endothelial 
GPR91 mRNA expression in large arteries. Similarly, GPR81 
does not co-localize with endothelial cell markers in the cere-
bral vasculature.16 Within the kidney, GPR81 was additionally 
expressed in glomerular arterioles, with a previous study re-
porting afferent arteriolar localization in dog and mouse.9 We 
detected GPR81 in perivascular cells, particularly, in the renal 
medulla and in isolated PDGFRβ+ cells. GPR81 also colocal-
izes with PDGFRβ-expressing cells and leptomeningeal cells 
in the cerebral microcirculation.16
This expression profile suggests that GPR81 is intimately 
involved in vascular/microvascular function, as described for 
other metabolic GPCRs. For example, activation of GPR109a 
by niacin reduces reactive oxygen production in arterial endo-
thelial cells20 and promotes vasodilation by stimulating pros-
taglandin production.21 Succinate, which activates GPR91, 
acutely increases circulating Ang II (angiotensin II) and BP 
in rats.22 Like GPR81, GPR91 is also coupled to G
i
, and 
Figure 3. Gpr81 (G-protein-coupled receptor 
81) expression in artery and renal cells. A, RNA 
was extracted and reverse transcribed from 
C57Bl/6JCrl mouse vessels. Negative controls 
were samples where reverse transcription 
enzyme, or RNA, were left out at the cDNA 
conversion step. All samples underwent end 
point polymerase chain reaction (PCR) before 
gel electrophoresis. n=4 for all vessel types, 
pooled from 2 mice for renal arteries and 
mesenteric arteries. B, Defined populations of 
cells were isolated by fluorescence-activated 
cell sorting (FACS) from kidney taken from 
n=4 mice. Quantitative PCR was used to 
measure Gpr81 in PDGFRβ+ (pericytes), CD31+ 
(endothelial cells), F4/80+ (macrophages), and 
LTL+ (tubule) cell groups. Expression was 
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succinate has direct effects on arterial contractility.23 For lac-
tate/GPR81, however, functional data are limited. Increasing 
lactate concentration in the brain, either through exercise 
or by exogenous administration, promotes angiogenesis.16 
This effect is GPR81-dependent since lactate-induced angi-
ogenesis does not occur in Gpr81−/− mice. Lactate also con-
stricts retinal microvessels, but it is not known whether this 
is GPR81–mediated.17 Infusion of very high concentrations 
of lactate increases BP in rats,24 most likely reflecting panic-
induced sympathoexcitation, rather than activation of GPR81.
The recent development of potent GPR81 agonists to treat 
dyslipidemia8,9,25 provides tools to probe the cardiovascular 
physiology of GPR81. One study has examined this, finding 
that structurally distinct GPR81 agonists increased SBP by 
≈15 mm Hg in rats and dogs when given intravenously and 
by ≈5 mm Hg in mice when given orally.9 Our studies con-
firm and extend this work, unequivocally demonstrating that 
one of these compounds, AZ′5538, increases BP dependent 
on the expression of GPR81. We further show that GPR81 ac-
tivation reduces renal artery flow, cortical and medullary per-
fusion, and GFR. The rapid increase in BP makes it difficult 
to unambiguously interpret these renal hemodynamic effects 
of AZ′5538. However, RBF and cortical perfusion normally 
autoregulate when BP increases,26,27 and our data most likely 
reflect direct vasoconstriction of the renal artery and preferen-
tial constriction of the afferent over efferent arteriole, account-
ing for the GFR reduction. Furthermore, expression of GPR81 
in renal PDGFRβ cells is consistent with localization in peri-
cytes, contractile cells which regulate vasa recta blood flow,28 
independent of changes in total or cortical blood flow.29 Thus, 
pericyte constriction may contribute to reduced intrarenal per-
fusion following GPR81 activation, but this was not demon-
strated directly.
The cellular mechanism underpinning GPR81-mediated 
vasoconstriction is not fully known. In adipocytes, GPR81 
couples to G
i
, downregulating cAMP production and protein 
Figure 4. Representative figures of Gpr81 
in situ hybridization. Positive Gpr81 mRNA 
expression shown by red punctuated dots. 
Expression found in wild-type (WT) mouse 
glomeruli of the kidney cortex (A) where the 
star indicates an arteriole and medulla (C). No 
staining was seen in Gpr81−/− mouse kidney 
tissues (B and D). Receptor expression also 
seen in smooth muscle cells of the WT mouse 
aorta (E) and renal artery (F) where staining is 
indicated with arrows. Scale bars are 50 μm 
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kinase A signaling.30 Activation of G
i
 pathways in vascular 
smooth muscle cells, by GPCR kinase 5, for example, low-
ers intracellular cAMP (Cyclic adenosine monophosphate), 
enhances vasoconstriction, and causes sustained hyperten-
sion.31 Similarly, activation of A1 receptors by adenosine 
constricts the renal afferent arteriole by a G
i
-mediated cas-
cade involving activation of phospholipase C.32 Reciprocally, 
agents that increase cAMP promote arterial vasorelaxation.33,34 
However, our data do not support a direct vasomotor effect of 
GPR81 activation and instead indicate dependency on ET-1 
release and subsequent endothelin-A receptor activation. 
Notably, ET-1 is synthesized by arterial myocytes,35 a cell that 
expresses GPR81. Further, a reduction in cAMP stimulates 
the production of ET-1 by myocytes,36–38 as does vascular di-
sease and injury.39,40 The hemodynamic response to AZ′5538 
is also consistent with this sequence: ET-1, via endothelin-A 
receptors, induces a stronger constriction of the afferent than 
efferent arteriole41 and also causes pericyte contraction, re-
ducing vasa recta blood flow,42 both of which were found in 
our study.
In the final series of experiments, renal IRI was in-
duced as this is known to increase intrarenal extracellular 
lactate.43 We selected a panel of transcriptional markers to 
capture cardinal features of IRI, tubular injury (KIM-1), 
increased matrix deposition (collagen 1a1), enhanced intra-
renal cytokine production (TNF-α, CXCL-1, CXCL-10), 
and increased monocyte/macrophage infiltration (F4/80). 
In wild-type mice, ischemia-reperfusion increased expres-
sion of these markers, as anticipated. In contrast, this tran-
scriptional response to ischemia-reperfusion was absent or 
blunted in Gpr81−/− mice. Similar outcomes are reported in 
cerebral ischemic injury: 3-hydroxy-butyrate, which antago-
nizes GPR81, prevents lactate-induced injury in primary 
cultured neurons and is neuroprotective in mice exposed to 
cerebral artery occlusion.13 In contrast, overexpression of 
GPR81 amplifies sensitivity to hypoxic injury in a neuronal 
cell line.13
We cannot unequivocally establish the mechanism of reno-
protection in Gpr81−/− mice, but these animals did not display 
the sustained post-ischemic increase in renal ET-1 expression 
that occurred in wild-type mice. This is likely to be important 
for at least 2 reasons. First, endothelin-A receptor–dependent 
vasoconstriction may contribute to progressive renal injury, 
which has a strong hemodynamic component.44 Second, ET-1, 
via endothelin-B receptors, can drive epithelial-mesenchymal 
transition and promote renal fibrosis.45 Gpr81−/− mice did not 
respond to ischemia-reperfusion with an increase in TNF-α or 
collagen 1a1 production, and the disconnection between ex-
tracellular lactate and ET-1 may account for this.
A limitation of our work is that all of the studies were per-
formed on male mice. Although recent studies show that sex 
does not influence afferent arteriolar reactivity to ET-1,46 other 
literature indicates sex differences in the renal actions of ET-1, 
which might be particularly relevant in an injury context.47 
Figure 5. Role of the endothelin system. A, The change in plasma endothelin-1 in C57Bl/6J mice infused with either vehicle (open square; n=8) or AZ′5538 
(1 µmol/[kg·min] black square; n=8) for 15 min. Individual data points and mean±SD are shown. In separate experiments, C57Bl/6J was infused intravenously 
with vehicle or an endothelin receptor antagonist for 25 min before treatment with AZ′5538 (1 µmol/[kg·min] for 15 min). The change in systolic blood 
pressure over baseline is shown. B, Bosentan; C, BQ123; and D, BQ788. Data are mean±SD, analyzed by 2-way ANOVA. Statistical comparisons were made 
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For example, post ischemia-reperfusion, male rats display an 
exaggerated early increase in renal vascular resistance and 
then a more pronounced decline in renal function and lower 
survival rate than do female rats.48 Furthermore, IRI increased 
ET-1 expression in male rats and prophylactic endothelin-A 
blockade improved survival.48 In marked contrast, endothelin-
A receptor blockade in females was detrimental, worsening 
post-ischemic survival rates, suggesting a protective role of 
ET-1/endothelin-A receptors activation. Overall, these data in-
dicate that female Gpr81−/− may not show the post-ischemic 
renoprotection of male animals identified by the current study.
Perspectives
In summary, our study indicates that GPR81 activation regu-
lates macro- and microvascular perfusion within the kidney, 
dependent on ET-1 signaling. The physiological requirement 
for a system that would lead to vasoconstriction of regions 
with high anaerobic cellular metabolism is not readily appar-
ent, given the injurious effect of hypoxia. However, earlier 
work in skeletal muscle associated exercise-induced accumu-
lation of extracellular lactate with the release of ET-1 and pro-
posed that constraining vasodilation of the skeletal vasculature 
would help maintain systemic BP during exercise.49 It may be 
that GPR81 activation similarly constrains the propensity to 
increase flow into relatively ischemic areas of the kidney and 
thereby militates against hyperemic damage. Additionally, the 
ET-1 release may contribute to vascular remodeling with sus-
tained hypoxia. Overall, our data suggest that blockade of the 
GPR81/ET-1 system could offer beneficial vascular support in 
the post-injury phase.50
Figure 6. Gpr81−/− mice have reduced injury 
following renal ischemia-reperfusion. Renal 
ischemia-reperfusion injury or a sham operation 
was performed on Gpr81−/− (n=4/6) and 
wild-type mice (n=6/4). One week later, the 
renal expression of the following genes was 
measured by quantitative polymerase chain 
reaction: (A) Havcr1 (encoding KIM-1 [kidney 
injury molecule 1]); (B) Col1a1 (encoding 
collagen type 1 α1); (C) Tnf (encoding TNF-α 
[tumor necrosis factor-α], ); (D) Ccl2 (encoding 
MCP-1 [monocyte chemotactic protein 1]); (E) 
Cxcl1 (encoding C-X-C motif chemokine ligand 
1); and (F) Edn1 (encoding preproendothelin-1). 
Expression is normalized to housekeepers; 
individual data points and group mean±SD are 
shown. Statistical comparisons were made by 
1-way ANOVA with Holm-Sidak test for planned 
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What Is New?
•	Activation of GPR81 (G-protein-coupled receptor 81) increases blood 
pressure, induces renal vascular and microvascular constriction, and 
reduces glomerular filtration rate.
•	The systemic and renal hemodynamic effects are mediated by release of 
ET-1 (endothelin-1) and activation of the endothelin-A receptor.
•	Gpr81 is localized to arterial vascular smooth muscle, to the arterioles, 
and in pericytes that influence capillary blood flow.
•	Genetic deletion of Gpr81 in mice protects against renal ischemic injury.
What Is Relevant?
•	The endogenous ligand for GPR81 is lactate. Our results suggest that 
lactate, via activation of GPR81, may contribute to the physiological reg-
ulation of blood pressure and renal hemodynamics.
•	GPR81 antagonists may offer a route for vascular support in renal ische-
mia, the most common cause of acute kidney injury in humans.
Summary
In male mice, activation of GPR81 increased blood pressure and 
reduced renal artery blood flow, renal capillary perfusion, and glo-
merular filtration rate. GPR81 activation rapidly increased plasma 
ET-1: the pressor effects were prevented by selective endothelin-A 
receptor antagonism. In male wild-type mice, ischemia-reperfu-
sion increased renal expression of ET-1 and genes associated with 
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